Cassava Sciences, Inc. (SAVA)
PHARMACEUTICAL PREPARATIONS
Cassava Sciences, Inc. (SAVA) was listed on Nasdaq from July 14, 2000 and stopped trading under the symbol SAVA on March 11, 2026.
- Listed On
- Nasdaq
- Listed Since
- July 14, 2000
- Stopped Trading
- March 11, 2026
- Employees
- 30
About Cassava Sciences, Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Frequently asked questions
What is SAVA?
Cassava Sciences, Inc. (SAVA) was listed on Nasdaq from July 14, 2000 and stopped trading under the symbol SAVA on March 11, 2026.
Every reported institutional holder, plus insider and congressional trades in SAVA, on SentiSense.